Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Filtros aplicados
Base de dados
Intervalo de ano de publicação
1.
Nutr. hosp ; 38(6)nov.-dic. 2021. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-224847

RESUMO

Introducción: se han realizado investigaciones sobre la diabetes con péptidos de diferentes fuentes alimentarias en animales experimentales para aplicarse después en los seres humanos. Objetivo: la finalidad de este trabajo fue evaluar en ratas el efecto hipoglucemiante de una fracción peptídica de chía obtenida por hidrólisis enzimática. Materiales y métodos: de la harina de chía se obtuvo una fracción rica en proteína que fue hidrolizada con pepsina-pancreatina, generándose una fracción peptídica (> 10 kDa) por ultrafiltración. Se utilizaron cinco grupos de ratas (uno de normoglucémicas y cuatro de diabetizadas con aloxano). Se realizó una curva de tolerancia a la sacarosa, proporcionándoles el disacárido antes de la medición. La sangre se tomó de la punta de la cola a los 0, 30, 60, 90 y 120 minutos. Resultados: el contenido proteico de la harina fue del 49,51 %. La fracción peptídica (> 10 kDa) presentó un 91 % de proteína; de esta se suministró una dosis de 50 mg/kg que demostró una tendencia a la disminución de la glucosa sanguínea en la primera hora, aunque no se encontró significancia entre el blanco y las dosis evaluadas. No hubo disminución de la absorción de glucosa frente al fármaco de referencia. A los 120 min del periodo postprandial no se encontraron diferencias entre las dosis, el blanco y la acarbosa, lo que denota un retorno al estado basal. Los valores en las ratas diabetizadas fueron opuestos a los de la acarbosa, por lo que no existió relación entre el mecanismo de acción del fármaco con el efecto analizado. Conclusión: las fracciones peptídicas de chía de > 10 kDa no presentaron efecto hipoglucemiante con la dosis única suministrada. (AU)


Introduction: diabetes research with peptides from foods has been conducted in animal experiments to be later applied to humans. Objective: the main purpose of this work was to evaluate in rats the hypoglycemic effect of a peptide fraction of chia seeds derived by enzymatic hydrolysis. Materials and methods: from chia flour a protein-rich fraction was obtained, which was hydrolyzed with pepsin-pancreatin system enzymes to yield a peptide fraction (> 10 kDa) by ultrafiltration. Five rat groups (one normoglycemic and four diabetized with alloxan) were used. A sucrose tolerance curve was performed, providing the disaccharide before measurement. Blood was taken from the tip of the tail at 0 (before sugar), 30, 60, 90, and 120 minutes. Results: the protein content of chia flour was 49.51 %. The peptide fraction (> 10 kDa) had 91 % of protein. A dose of 50 mg/kg showed in rats a tendency to decrease blood glucose within the first hour, but no significance was found between the target and the doses evaluated. There was no decrease in glucose absorption vs. the reference drug. At 120 min postprandial, no differences were found between doses, water, and acarbose, showing a return to the baseline status. The tolerance curve in diabetic rats was opposite to that of acarbose, so there was no relationship between the drug's mechanism of action and this analyzed effect. Conclusion: the peptide fraction of chia of > 10 kDa showed no hypoglycemic effect at the single dose that was administered. (AU)


Assuntos
Animais , Ratos , Glicemia/efeitos dos fármacos , Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemia/etiologia , Extratos Vegetais/administração & dosagem , Glicemia/análise , Aloxano/efeitos adversos , Aloxano/farmacocinética , Diabetes Mellitus Experimental/fisiopatologia , Modelos Animais de Doenças , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Ratos Wistar
2.
Nutr. hosp ; 37(2): 343-348, mar.-abr. 2020. tab, graf
Artigo em Inglês | IBECS | ID: ibc-190600

RESUMO

INTRODUCTION: diabetes mellitus is considered a chronic disease, characterized by the presence of high glycemic concentrations and dyslipidemia or hyperlipidemia caused by absence or deficiency of insulin secretion by pancreatic β-cells. Micro and macrovascular complications may lead to nephropathy. Diabetic syndrome and oxidative damage are strongly related. The guarana plant (Paullinia cupana) has been described as an antioxidant agent. OBJECTIVE: this study aims to evaluate the protective action of the guarana compound on the biochemical profile of alloxan-induced diabetes in rats. METHOD: twenty-eight male Wistar Furth rats were divided into four groups of seven animals each: the control group (CG) was fed a standard diet; the guarana group (GG) was fed a standard diet supplemented with guarana; the diabetic group (DG) included alloxan-induced diabetic rats fed a standard diet; and the diabetic guarana group (DGG) included alloxan-induced diabetic rats fed a standard diet supplemented with guarana. Induction was performed by intraperitoneal injection of alloxan 150 mg/kg. RESULTS: LDL (CG: 24.64 ± 2,59; GG: 38.93 ± 7.19; DG: 14.9 ± 3.96; DGG: 20.8 ± 4.04 mg/dL); HDL (CG: 14.8 ± 4.86; GG: 13 ± 1.41; DG: 22.5 ± 7.81; DGG: 30.66 ± 9.02 mg/dL); ALT (CG: 31.8 ± 4.81; GG: 22.16 ± 1.83; DG: 38 ± 1.4; DGG: 26.83 ± 2.13 U/L); AST (CG: 101.8 ± 5.07; GG: 117.5 ± 9.73; DG: 183.6 ± 4.21; DGG: 116.16 ± 12 U/L); urea (CG: 51.4 ± 5.03; GG: 42.5 ± 8.24; DG: 129.16 ± 31.72; DGG: 150.5 ± 36.02 mg/dL); creatinine (CG: 0.6 ± 0.12; GG: 0.53 ± 0.05; DG: 0.78 ± 0.11; DGG: 0.61 ± 0.07 mg/dL). CONCLUSIONS: consumption of guarana (Paullinia cupana) by male Wistar Furth rats with alloxan induced diabetes without treatment had a beneficial effect on hepatic and renal function parameters, and raises the possibility of being used as supportive therapy in the treatment of diabetes


INTRODUCCIÓN: la diabetes mellitus (DM) se considera una enfermedad crónica caracterizada por la presencia de altas concentraciones glucémicas, dislipidemia o hiperlipidemia causadas por ausencia o deficiencia de la secreción de insulina por las células β del páncreas. Sus complicaciones micro y macrovasculares pueden llevar a un cuadro de nefropatía. El síndrome diabético y el daño oxidativo están fuertemente relacionados. El guaraná (Paullinia cupana) se ha venido describiendo como un agente antioxidante. OBJETIVO: este estudio tiene el objetivo de evaluar la posible acción protectora de este compuesto sobre el perfil bioquímico de ratas con diabetes inducida por aloxano. MATERIAL Y MÉTODOS: veintiocho ratas macho Wistar Furth se dividieron en cuatro grupos de siete animales cada uno: el grupo de control (CG) se alimentó con la dieta estándar; el grupo de guaraná (GG) se alimentó con la dieta estándar complementada con guaraná; el grupo diabético (DG) se formó con ratas con diabetes inducida por aloxano que se alimentaron con la dieta estándar; el grupo diabético con guaraná (DGG) se formó con ratas con diabetes inducida por aloxano que se alimentaron con la dieta estándar complementada con guaraná. La inducción se realizó a través de una inyección intraperitoneal de aloxano en dosis de 150 mg/kg. RESULTADOS: LDL (CG: 24,64 ± 2,59; GG: 38,93 ± 7,19; DG: 14,9 ± 3,96; DGG: 20,8 ± 4,04 mg/dl); HDL (CG: 14,8 ± 4,86; GG: 13 ± 1,41; DG: 22,5 ± 7,81; DGG: 30,66 ± 9,02 mg/dl); ALT (CG: 31,8 ± 4,81; GG: 22,16 ± 1,83; DG: 38 ± 1,4; DGG: 26,83 ± 2,13 U/L); AST (CG: 101,8 ± 5,07; GG: 117,5 ± 9,73; DG: 183,6 ± 4,21; DGG: 116,16 ± 12 U/L); urea (CG: 51,4 ± 5,03; GG: 42,5 ± 8,24; DG: 129,16 ± 31,72; DGG: 150,5 ± 36,02 mg/dl); creatinina (CG: 0,6 ± 0,12; GG: 0,53 ± 0,05; DG: 0,78 ± 0,11; DGG: 0,61 ± 0,07 mg/dl). CONCLUSIÓN: el consumo de guaraná (Paullinia cupana) por ratas Wistar con diabetes inducida por aloxano y sin tratamiento actuó de forma beneficiosa sobre los parámetros hepáticos y de función renal, planteando la posibilidad de poder ser utilizado como terapia de soporte en el tratamiento de la diabetes


Assuntos
Animais , Feminino , Ratos , Paullinia , Diabetes Mellitus/induzido quimicamente , Diabetes Mellitus/veterinária , Aloxano/efeitos adversos , Fígado/efeitos dos fármacos , Aloxano/administração & dosagem , Células Secretoras de Insulina/efeitos dos fármacos , Ratos Endogâmicos WF
3.
J. physiol. biochem ; 69(1): 35-43, mar. 2013.
Artigo em Inglês | IBECS | ID: ibc-121985

RESUMO

Zinc has a role in the synthesis, storage, and secretion of insulin, and has been suggested to be beneficial when used in the diabetic state. Effect of zinc intake in pregnant rats has been studied here on diabetized offspring. Pregnant rats were divided in two groups; the control group received normal food and water, and the experimental group received zinc sulfate during pregnancy and 3 weeks after offspring birth. Male offspring from the control (C) and experimental (E) groups were divided each in three groups: C1, fed with normal food and water; C2, diabetized with alloxan; C3, received zinc sulfate; E1, fed with normal food and water; E2, diabetized with alloxan; and E3, receiving zinc sulfate. After 30 days, the histological changes of pancreatic tissues were investigated by light microscopy. Body weight, blood glucose, serum insulin levels, food intake, water intake, and urine quantity were also compared between the groups. Water intake and urine quantity were decreased significantly (p < 0.01and p < 0.001) in E2 (experimental diabetic group) in comparison with C2 (control diabetic group), but there was no significant difference in the body weight in C2 in comparison with E2, while blood glucose was decreased significantly (p < 0.001) and blood insulin level was increased significantly (p < 0.01) in E2 in comparison with C2. Microscopic evaluation of pancreas showed that E2 were protected against alloxan-induced beta-cell degeneration. In conclusion, this work showed that maternal zinc intake may influence subsequent deleterious effects of diabetes on alloxan-diabetized offspring (AU)


Assuntos
Animais , Gravidez , Ratos , Feminino , Zinco/farmacocinética , Diabetes Mellitus/prevenção & controle , Aloxano/farmacocinética , Pâncreas , Nutrição Materna , Modelos Animais de Doenças , Substâncias Protetoras/farmacocinética , Estudos de Casos e Controles
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...